^
Association details:
| Biomarker: | MET amplification |
|---|---|
| Cancer: | Gastroesophageal Cancer |
| Drug: | Orpathys (savolitinib) (c-MET inhibitor) + Tabrecta (capmatinib) (c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
3486 / 18 - Effect of MET tyrosine kinase inhibitors on MET amplified gastro-esophageal cancer cells
Published date:
03/09/2022
Excerpt:
We observed that treatment with savolitinib induced a significant decrease in the number of colonies formed in soft agar. In addition, Savolitinib exhibited dose-responsive anti-tumor efficacy in xenograft model with MKN-45 GC cells. Furthermore, the combination of Trastuzumab and capmatinib exhibited enhanced inhibition of AKT and ERK activation in OE-33 cells, which is positive for both HER2 and MET, and resistant to trastuzumab alone. Collectively, these data support that targeting MET with Savolitinib and capmatinib efficiently suppresses the growth of MET amplified GC cells.
